Homology Medicines

Drug development genetic diseases


HBM contact: Dr Ivo Staijen, Dr Chandra Leo

Company status: public

Homology develops novel gene therapy and gene editing approaches based on its proprietary, nuclease-free AMEnDR technology, with an initial focus on orphan diseases.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171